Aleksander Skulimowski
Research Subjects
Aleksander Skulimowski has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Adam Durczyński
Department of General and Transplant Surgery, Medical University of Lodz, 90-419 Lodz, Poland
6 shared publications - Piotr Hogendorf
Department of General and Transplant Surgery, Medical University of Lodz, Poland
5 shared publications Anna Kumor
Klinika Pneumonologii i Alergologii, Uniwersytet Medyczny w Łodzi
4 shared publicationsJanusz Strzelczyk
Department of General and Transplant Surgery, N. Barlicki Memorial Clinical Hospital, Medical University of Lodz, Lodz, Poland
4 shared publicationsGrażyna Poznańska
Klinika Anestezjologii i Intensywnej Terapii, Uniwersytet Medyczny w Łodzi
3 shared publications- Janusz Strzelczyk
Department of General and Transplant Surgery, Medical University of Lodz, Poland
3 shared publications
Latest Publications
- Open Access
- 28 July 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1831764
Can neoadjuvant endocrine therapy de-escalate surgery in luminal breast cancer? A four-year retrospective study from a single referral center
Introduction: Postmenopausal women commonly present with HR-positive/HER2-negative breast cancer. Neoadjuvant endocrine therapy (NET) may facilitate breast-conserving surgery (BCS) and de-escalation of axillary surgery. This study evaluated NET efficacy in enabling surgical de-escalation in luminal breast cancer. Materials and methods: A retrospective study included postmenopausal women (≥49 years) with newly diagnosed, luminal breast cancer treated with NET between May 2021 and May 2024 at a single tertiary breast unit. Patients with stage IV disease or contraindications to surgery were excluded. Clinical and pathologic variables were collected from chart review. Tumor and nodal downstaging were defined by decrease of at least one level from clinical (cT or cN) to pathologic (ypT or ypN) stage. Multivariable logistic regression was used to identify predictors of downstaging. Results: A total of 124 patients (128 tumors) were included. Mean age at diagnosis was 69 years. NET resulted in a significant reduction in tumor size (mean absolute reduction 10.93 mm; p < 0.0001; mean relative reduction 23.4%; p < 0.0001). BCS was achieved in 75.8% of cases, and NET was estimated to have avoided mastectomy in at least 27 patients. Lobular histology (OR 2.92, 95% CI 1.20–7.00; p = 0.017) and absence of clinical nodal involvement (OR 3.10, 95% CI 1.45–6.55; p = 0.003) were independently associated with T-stage downstaging. Regarding axillary management, 75.8% underwent sentinel lymph node biopsy and 22.7% upfront axillary lymph node dissection. Among patients initially managed with SLNB, 35% required completion ALND. Of 60 clinically node-positive (cN1) patients, 8 (12.7%) achieved ypN0 status after NET. Micrometastatic residual disease was observed in 4 additional cases (6.3% of cN1 patients). Conclusions: NET effectively facilitates breast-conserving surgery in postmenopausal patients with luminal breast cancer. However, its impact on achieving nodal clearance and reducing axillary dissection remains limited.
- 28 July 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1831764
Open AccessCan neoadjuvant endocrine therapy de-escalate surgery in luminal breast cancer? A four-year retrospective study from a single referral center
Introduction: Postmenopausal women commonly present with HR-positive/HER2-negative breast cancer. Neoadjuvant endocrine therapy (NET) may facilitate breast-conserving surgery (BCS) and de-escalation of axillary surgery. This study evaluated NET efficacy in enabling surgical de-escalation in luminal breast cancer. Materials and methods: A retrospective study included postmenopausal women (≥49 years) with newly diagnosed, luminal breast cancer treated with NET between May 2021 and May 2024 at a single tertiary breast unit. Patients with stage IV disease or contraindications to surgery were excluded. Clinical and pathologic variables were collected from chart review. Tumor and nodal downstaging were defined by decrease of at least one level from clinical (cT or cN) to pathologic (ypT or ypN) stage. Multivariable logistic regression was used to identify predictors of downstaging. Results: A total of 124 patients (128 tumors) were included. Mean age at diagnosis was 69 years. NET resulted in a significant reduction in tumor size (mean absolute reduction 10.93 mm; p < 0.0001; mean relative reduction 23.4%; p < 0.0001). BCS was achieved in 75.8% of cases, and NET was estimated to have avoided mastectomy in at least 27 patients. Lobular histology (OR 2.92, 95% CI 1.20–7.00; p = 0.017) and absence of clinical nodal involvement (OR 3.10, 95% CI 1.45–6.55; p = 0.003) were independently associated with T-stage downstaging. Regarding axillary management, 75.8% underwent sentinel lymph node biopsy and 22.7% upfront axillary lymph node dissection. Among patients initially managed with SLNB, 35% required completion ALND. Of 60 clinically node-positive (cN1) patients, 8 (12.7%) achieved ypN0 status after NET. Micrometastatic residual disease was observed in 4 additional cases (6.3% of cN1 patients). Conclusions: NET effectively facilitates breast-conserving surgery in postmenopausal patients with luminal breast cancer. However, its impact on achieving nodal clearance and reducing axillary dissection remains limited.
- 29 December 2023
- Published by Wojskowy Instytut Medyczny – Panstwowy Instytut Badawczy in Lekarz Wojskowy
- Vol. 101 (4) , 324-328
Microbiome in Pancreatic Fluid - Preliminary Analysis of Pancreatic Cystic Lesions
Introduction and objective: One of the main precursory lesions for pancreatic carcinoma is pancreatic cystic neoplasm. Differentiation between the various types of cysts is a clinical challenge. The microbiome colonizing the pancreatic cyst fluid is mostly unknown. The aim of the study was...
- 29 December 2023
- Published by Wojskowy Instytut Medyczny – Panstwowy Instytut Badawczy in Lekarz Wojskowy
- Vol. 101 (4) , 324-328
Microbiome in Pancreatic Fluid - Preliminary Analysis of Pancreatic Cystic Lesions
Introduction and objective: One of the main precursory lesions for pancreatic carcinoma is pancreatic cystic neoplasm. Differentiation between the various types of cysts is a clinical challenge. The microbiome colonizing the pancreatic cyst fluid is mostly unknown. The aim of the study was...
- 31 January 2021
- Published by Taylor & Francis in Biomarkers
- Vol. 26 (4) , 287-295
Comparison of clinical usefulness of serum Ca125 and CA19-9 in pancreatic adenocarcinoma diagnosis: meta-analysis and systematic review of literature
Introduction: Pancreatic adenocarcinoma remains one of the most lethal cancers. The only recommended biomarker CA19-9 proves to be not accurate enough to establish a certain diagnosis. Therefore a determination of usefulness of other biomarkers is essential. Our aim was to compare the specificity and sensitivity of Ca125 and CA19-9 by means of meta-analysis. The systematic review of combined tests (CA19-9 + Ca125) was also performed. Methods: We conducted a systematic search of Medline (via PubMed) and Ovid. After screening of abstracts and the assessment of full-texts, 9 studies (number of patients, n = 1599) were included. Hierarchical summary receiver under operator curve (hsROC) model was applied to estimate the diagnostic accuracy. Results: CA19-9 sensitivity and specificity were 0,748 (95%CI 0,676-0,809) and 0,782 (95%CI 0,716-0,836) respectively. These values were estimated on 0,593 (95%CI 0,489-0,69) and 0,754 (95%CI 0,817-0,668) for Ca125. Regarding the heterogeneity of studies a strong threshold effect for Ca125 and moderate one for CA19-9 were found. Conclusions: Our meta-analysis did not prove the superiority of Ca125. It should be nevertheless noted that the sparsity of studies precludes accurate analysis of various factors’ influence. The review of proposed combined tests shows that CA19-9 + Ca125 models are generally characterized by higher sensitivity.
- 31 January 2021
- Published by Taylor & Francis in Biomarkers
- Vol. 26 (4) , 287-295
Comparison of clinical usefulness of serum Ca125 and CA19-9 in pancreatic adenocarcinoma diagnosis: meta-analysis and systematic review of literature
Introduction: Pancreatic adenocarcinoma remains one of the most lethal cancers. The only recommended biomarker CA19-9 proves to be not accurate enough to establish a certain diagnosis. Therefore a determination of usefulness of other biomarkers is essential. Our aim was to compare the specificity and sensitivity of Ca125 and CA19-9 by means of meta-analysis. The systematic review of combined tests (CA19-9 + Ca125) was also performed. Methods: We conducted a systematic search of Medline (via PubMed) and Ovid. After screening of abstracts and the assessment of full-texts, 9 studies (number of patients, n = 1599) were included. Hierarchical summary receiver under operator curve (hsROC) model was applied to estimate the diagnostic accuracy. Results: CA19-9 sensitivity and specificity were 0,748 (95%CI 0,676-0,809) and 0,782 (95%CI 0,716-0,836) respectively. These values were estimated on 0,593 (95%CI 0,489-0,69) and 0,754 (95%CI 0,817-0,668) for Ca125. Regarding the heterogeneity of studies a strong threshold effect for Ca125 and moderate one for CA19-9 were found. Conclusions: Our meta-analysis did not prove the superiority of Ca125. It should be nevertheless noted that the sparsity of studies precludes accurate analysis of various factors’ influence. The review of proposed combined tests shows that CA19-9 + Ca125 models are generally characterized by higher sensitivity.
- Open Access
- 21 April 2020
- Published by Springer Nature in Research Square
Comparison of clinical usefulness of serum Ca125 and CA19-9 in pancreatic adenocarcinoma diagnosis: meta-analysis and systematic review of literature.
Background: Pancreatic adenocarcinoma remains one of the most lethal cancers. This is caused by its late manifestation and lack of extensively available, highly accurate diagnostic tools. The only recommended biomarker CA19-9 proves to be not accurate enough to establish a certain diagnosis. Therefore a standardization of usefulness of other biomarkers is essential. Consequently, our aim was to assess the specificity and sensitivity of Ca125 in comparison with CA19-9 by means of meta-analysis. The systematic review of combined tests (CA19-9+Ca125) was also carried out. Methods: We conducted a systematic search of Medline (via PubMed) and Ovid. After screening of abstracts and the assessment of full-texts, 9 studies (number of patients, n = 1599) were included in the meta-analysis. Hierarchical summary receiver under operator curve (hsROC) model was applied to estimate the diagnostic accuracy. Results: CA19-9 sensitivity and specificity were 0,748 (95%CI 0,676-0,809) and 0,782 (95%CI 0,716-0,836) respectively. These values were estimated on 0,593 (95%CI 0,489-0,69) and 0,754 (95%CI 0,817-0,668) for Ca125. Regarding the heterogeneity of studies we found a strong threshold effect for Ca125 and moderate one for CA19-9. Conclusions: Our meta-analysis did not prove the superiority of Ca125 in diagnosis of pancreatic adenocarcinoma. It should be nevertheless noted that analysed studies are encumbered with high heterogeneity mainly due to threshold effect. Moreover the sparsity of studies precludes accurate analysis of various factors’ influence. Therefore further research into Ca125 is warranted to fully elucidate its usefulness. The review of proposed combined tests shows that although CA19-9+Ca125 models are characterized by higher sensitivity, their usefulness is hampered by inferior specificity to than that of CA19-9 alone.
- 21 April 2020
- Published by Springer Nature in Research Square
Open AccessComparison of clinical usefulness of serum Ca125 and CA19-9 in pancreatic adenocarcinoma diagnosis: meta-analysis and systematic review of literature.
Background: Pancreatic adenocarcinoma remains one of the most lethal cancers. This is caused by its late manifestation and lack of extensively available, highly accurate diagnostic tools. The only recommended biomarker CA19-9 proves to be not accurate enough to establish a certain diagnosis. Therefore a standardization of usefulness of other biomarkers is essential. Consequently, our aim was to assess the specificity and sensitivity of Ca125 in comparison with CA19-9 by means of meta-analysis. The systematic review of combined tests (CA19-9+Ca125) was also carried out. Methods: We conducted a systematic search of Medline (via PubMed) and Ovid. After screening of abstracts and the assessment of full-texts, 9 studies (number of patients, n = 1599) were included in the meta-analysis. Hierarchical summary receiver under operator curve (hsROC) model was applied to estimate the diagnostic accuracy. Results: CA19-9 sensitivity and specificity were 0,748 (95%CI 0,676-0,809) and 0,782 (95%CI 0,716-0,836) respectively. These values were estimated on 0,593 (95%CI 0,489-0,69) and 0,754 (95%CI 0,817-0,668) for Ca125. Regarding the heterogeneity of studies we found a strong threshold effect for Ca125 and moderate one for CA19-9. Conclusions: Our meta-analysis did not prove the superiority of Ca125 in diagnosis of pancreatic adenocarcinoma. It should be nevertheless noted that analysed studies are encumbered with high heterogeneity mainly due to threshold effect. Moreover the sparsity of studies precludes accurate analysis of various factors’ influence. Therefore further research into Ca125 is warranted to fully elucidate its usefulness. The review of proposed combined tests shows that although CA19-9+Ca125 models are characterized by higher sensitivity, their usefulness is hampered by inferior specificity to than that of CA19-9 alone.
- 16 April 2020
- Published by Index Copernicus in Polish Journal of Surgery
- Vol. 92 (3) , 1-5
Elevated preoperative levels of CA 19-9 and CA 125 predicts overall survival time in the pancreatic adenocarcinoma. Single institution series.
Introduction: Pancreatic cancer is a devastating disease, being the seventh cause of cancer-related deaths worldwide. Its aggressiveness is due to its specific biology and the late diagnosis of cancer. Therefore, the prognosis for patients suffering from this cancer is dismal, with 5-year overall survival rate of around 6-10%. Up to date, only a complete surgical resection of the cancerous entity warrants a significant improvement in patients' survival. Nevertheless, the pancreatic cancer's biology is still not fully elucidated, so that the accuracy of prognosis for certain patients is highly uncertain. Consequently, the importance of both clinical and basic research aiming to reveal the crucial molecular factors affecting long-term prognosis should be highlighted. There is a growing number of evidence that biomarkers of PC not only reflect the presence of tumor itself but also present a "hint" regarding its physiology. Thus the aim of this study was to assess the levels of commonly measured biomarkers and their influence on patients' overall survival. Materials and methods: The retrospective analysis of data on 129 patients admitted to our Department due to the diagnosis of pancreatic cancer was carried out. On the day of admission all the patients had their levels of CA19-9, CA125, CEA and CA15-3 measured. The overall survival (OS) was defined as time elapsing from the day of admission to the day of death. The Kaplan- Meier curves were built for all potential factors, Cox regression model was applied to carry out a multivariate analysis. Results: We retrospectively analyzed 129 patients with a mean age of 62 years. As many as 95 of them had an unresectable lesion and 34 underwent curative operation. In total, the analyzed patient group was characterized by a median survival of 7 months and 12 days. Cumulative 1-year, 2-year and 4-year survival rates were 35%, 16% and 15%, respectively. In univariate analysis, factors such as age >= 60, inoperable lesion, CA19-9 >= 200, CA125 >= 20 and Neutrophile to Lymphocyte Ratio (NLR) >= 5 were associated with a lower median OS. In multivariate analysis, three factors, CA19-9 >= 200, CA125 >= 20 and age >= 60, were found to be statistically significant. Indeed, patients possessing all of them noted much poorer outcomes regarding OS factors: 89 days versus 235 days for the other patients (log rank test P = 0.02). Conclusions: Our study fortifies the evidence that preoperative levels of CA19-9 and CA125 have a direct influence on the longterm OS. Interestingly, in our patient group, the correlation of biomarkers with OS was higher than that of resectability. However, our study has some limitations regarding, for instance, the lack of data on chemotherapy, comorbidities etc. In the view of recent molecular studies on mucin involvement in PC development, it provides a strong clinical evidence to prove their importance.
- 16 April 2020
- Published by Index Copernicus in Polish Journal of Surgery
- Vol. 92 (3) , 1-5
Elevated preoperative levels of CA 19-9 and CA 125 predicts overall survival time in the pancreatic adenocarcinoma. Single institution series.
Introduction: Pancreatic cancer is a devastating disease, being the seventh cause of cancer-related deaths worldwide. Its aggressiveness is due to its specific biology and the late diagnosis of cancer. Therefore, the prognosis for patients suffering from this cancer is dismal, with 5-year overall survival rate of around 6-10%. Up to date, only a complete surgical resection of the cancerous entity warrants a significant improvement in patients' survival. Nevertheless, the pancreatic cancer's biology is still not fully elucidated, so that the accuracy of prognosis for certain patients is highly uncertain. Consequently, the importance of both clinical and basic research aiming to reveal the crucial molecular factors affecting long-term prognosis should be highlighted. There is a growing number of evidence that biomarkers of PC not only reflect the presence of tumor itself but also present a "hint" regarding its physiology. Thus the aim of this study was to assess the levels of commonly measured biomarkers and their influence on patients' overall survival. Materials and methods: The retrospective analysis of data on 129 patients admitted to our Department due to the diagnosis of pancreatic cancer was carried out. On the day of admission all the patients had their levels of CA19-9, CA125, CEA and CA15-3 measured. The overall survival (OS) was defined as time elapsing from the day of admission to the day of death. The Kaplan- Meier curves were built for all potential factors, Cox regression model was applied to carry out a multivariate analysis. Results: We retrospectively analyzed 129 patients with a mean age of 62 years. As many as 95 of them had an unresectable lesion and 34 underwent curative operation. In total, the analyzed patient group was characterized by a median survival of 7 months and 12 days. Cumulative 1-year, 2-year and 4-year survival rates were 35%, 16% and 15%, respectively. In univariate analysis, factors such as age >= 60, inoperable lesion, CA19-9 >= 200, CA125 >= 20 and Neutrophile to Lymphocyte Ratio (NLR) >= 5 were associated with a lower median OS. In multivariate analysis, three factors, CA19-9 >= 200, CA125 >= 20 and age >= 60, were found to be statistically significant. Indeed, patients possessing all of them noted much poorer outcomes regarding OS factors: 89 days versus 235 days for the other patients (log rank test P = 0.02). Conclusions: Our study fortifies the evidence that preoperative levels of CA19-9 and CA125 have a direct influence on the longterm OS. Interestingly, in our patient group, the correlation of biomarkers with OS was higher than that of resectability. However, our study has some limitations regarding, for instance, the lack of data on chemotherapy, comorbidities etc. In the view of recent molecular studies on mucin involvement in PC development, it provides a strong clinical evidence to prove their importance.
- 25 September 2017
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 52 (12) , 1442-1452
Colorectal endoscopic submucosal dissection (ESD) in the West – when can satisfactory results be obtained? A single-operator learning curve analysis
Up to date we lack a detailed description of the colorectal endoscopic submucosal dissection (ESD) learning curve, that would represent the experience of the Western center. The aim of this study was to define the critical points of the learning curve and to draw up lesions qualification guidelines tailored to the endoscopists experience. We have carried out a single center prospective study. Between June 2013 and December 2016, 228 primary colorectal lesions were managed by ESD procedure. In order to create a learning curve model and to carry out the analysis the cases were divided into six periods, each consisting of 38 cases. The overall en bloc resection rate was 79.39%. The lowest en bloc resection rate (52.36%) was observed in the first period. After completing 76 procedures, the resection rate surged to 86% and it was accompanied by the significant increase in the mean procedure speed of ≥9 cm2/h. Lesions localization and diameter had a signification impact on the outcomes. After 76 procedures, en bloc resection rate of 90.9 and 90.67% were achieved for the left side of colon and rectum, respectively. In the right side of colon statistically significant lower resection rate of 67.57% was observed. We have proved that in the setting of the Western center, colorectal ESD can yield excellent results. It seems that the key to the success during the learning period is 'tailoring' lesions qualification guidelines to the experience of the endoscopist, as lesions diameter and localization highly influence the outcomes.
- 25 September 2017
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 52 (12) , 1442-1452
Colorectal endoscopic submucosal dissection (ESD) in the West – when can satisfactory results be obtained? A single-operator learning curve analysis
Up to date we lack a detailed description of the colorectal endoscopic submucosal dissection (ESD) learning curve, that would represent the experience of the Western center. The aim of this study was to define the critical points of the learning curve and to draw up lesions qualification guidelines tailored to the endoscopists experience. We have carried out a single center prospective study. Between June 2013 and December 2016, 228 primary colorectal lesions were managed by ESD procedure. In order to create a learning curve model and to carry out the analysis the cases were divided into six periods, each consisting of 38 cases. The overall en bloc resection rate was 79.39%. The lowest en bloc resection rate (52.36%) was observed in the first period. After completing 76 procedures, the resection rate surged to 86% and it was accompanied by the significant increase in the mean procedure speed of ≥9 cm2/h. Lesions localization and diameter had a signification impact on the outcomes. After 76 procedures, en bloc resection rate of 90.9 and 90.67% were achieved for the left side of colon and rectum, respectively. In the right side of colon statistically significant lower resection rate of 67.57% was observed. We have proved that in the setting of the Western center, colorectal ESD can yield excellent results. It seems that the key to the success during the learning period is 'tailoring' lesions qualification guidelines to the experience of the endoscopist, as lesions diameter and localization highly influence the outcomes.
- Open Access
- 5 March 2017
- Published by Wiley in Disease Markers
- Vol. 2017, 1-9
A Panel of CA19-9, Ca125, and Ca15-3 as the Enhanced Test for the Differential Diagnosis of the Pancreatic Lesion
Background. Proper diagnosis of pancreatic lesion etiology is a challenging clinical dilemma. Studies suggest that surgery for suspected pancreatic ductal adenocarcinoma (PDAC) reveals a benign lesion in 5% to 13% of cases. The aim of our study was to assess whether routinely used biomarkers such as CA19-9, Ca125, Ca15-3, and CEA, when combined, can potentially yield an accurate test predicting pancreatic lesion etiology. Methods. We retrospectively analyzed data of 326 patients who underwent a diagnostic process due to pancreatic lesions of unknown etiology. Results. We found statistically significant differences in mean levels of all biomarkers. In logistic regression model, we applied levels CA19-9, Ca125, and Ca15-3 as variables. Two validation methods were used, namely, random data split into training and validation groups and bootstrapping. Afterward, we built ROC curve using the model that we had created, reaching AUC = 0,801. With an optimal cut-off point, it achieved specificity of 81,2% and sensitivity of 63,10%. Our proposed model has superior diagnostic accuracy to both CA19-9 ( = 0,0194) and CA125 ( = 0,0026). Conclusion. We propose a test that is superior to CA19-9 in a differential diagnosis of pancreatic lesion etiology. Although our test fails to reach exceptionally high accuracy, its feasibility and cost-effectiveness make it clinically useful.- 5 March 2017
- Published by Wiley in Disease Markers
- Vol. 2017, 1-9
Open AccessA Panel of CA19-9, Ca125, and Ca15-3 as the Enhanced Test for the Differential Diagnosis of the Pancreatic Lesion
Background. Proper diagnosis of pancreatic lesion etiology is a challenging clinical dilemma. Studies suggest that surgery for suspected pancreatic ductal adenocarcinoma (PDAC) reveals a benign lesion in 5% to 13% of cases. The aim of our study was to assess whether routinely used biomarkers such as CA19-9, Ca125, Ca15-3, and CEA, when combined, can potentially yield an accurate test predicting pancreatic lesion etiology. Methods. We retrospectively analyzed data of 326 patients who underwent a diagnostic process due to pancreatic lesions of unknown etiology. Results. We found statistically significant differences in mean levels of all biomarkers. In logistic regression model, we applied levels CA19-9, Ca125, and Ca15-3 as variables. Two validation methods were used, namely, random data split into training and validation groups and bootstrapping. Afterward, we built ROC curve using the model that we had created, reaching AUC = 0,801. With an optimal cut-off point, it achieved specificity of 81,2% and sensitivity of 63,10%. Our proposed model has superior diagnostic accuracy to both CA19-9 ( = 0,0194) and CA125 ( = 0,0026). Conclusion. We propose a test that is superior to CA19-9 in a differential diagnosis of pancreatic lesion etiology. Although our test fails to reach exceptionally high accuracy, its feasibility and cost-effectiveness make it clinically useful. - 1 January 2017
- Published by Wolters Kluwer Health in Pancreas
- Vol. 46 (1) , e9-e10
Concentration of D-dimers in Bile—a Novel Marker of Pancreatic Cancer Enhancing Accuracy of Standard CA19-9 Measurement
- 1 January 2017
- Published by Wolters Kluwer Health in Pancreas
- Vol. 46 (1) , e9-e10
Concentration of D-dimers in Bile—a Novel Marker of Pancreatic Cancer Enhancing Accuracy of Standard CA19-9 Measurement
- 13 April 2016
- Published by SAGE Publications in Cancer Biomarkers
- Vol. 16 (4) , 537-543
Neutrophil Gelatinase-Associated Lipocalin (NGAL) concentration in urine is superior to CA19-9 and Ca 125 in differentiation of pancreatic mass: Preliminary report
Currently pancreatic cancer is the fourth leading cause of cancer-related death worldwide. Because of its late manifestation and consequent dismal prognosis, there is an urgent need to develop highly sensitive and specific marker. Neutrophil Gelatinase-Associated Lipocalin (NGAL) recently emerged as a protein playing an important role in carcinogenesis of various neoplasms. Our aim was to assess the potential of urine and bile concentration of NGAL in differentiating pancreatic adenocarcinoma from chronic pancreatitis. Forty-two patients operated on due to pancreatobiliary lesions were enrolled in this study. All enrolled patients had eGFR within reference range. Levels of CEA, CA 125 and Ca19-9 were assessed using standard laboratory protocols. A sample of urine was collected prior to the surgery. Intraoperatively a 5 ml sample of bile was collected directly from the common bile duct. Bile and urine levels of NGAL were measured using a ELISA kit. After standard pathological examination of specimens obtained during surgery, patients were divided into 2 groups: 21 patients with pancreatic adenocarcinoma and 15 patients with focal chronic pancreatitis. NGAL concentration in bile in patients with PDAC vs CP was 75.72 ± 16.05 ng/mL vs 62.62 ± 18.6 ng/mL respectively (p= 0,011). NGAL concentration in urine was 43.26 ± 21.21 ng/mL vs 17.96 ± 14.58 ng/mL (p= 0.002) respectively. In order to compare these markers with routinely used ones, ROC curve was built for Ca125 to establish cutoff point and in case of CA19-9 clinically used cutoff (≥ 37U/mL) was applied. Sensitivity and specificity for NGALurine with cutoff value of 27 ng/mL was 80.95% and 80% respectively, while these values for NGALbile were 71.43% and 80% respectively. Ca19-9 measured in plasma with clinically used cutoff value had sensitivity of 71.43% and specificity of 73.33%. Sensitivity and specificity for Ca 125 measured in plasma with cutoff value of 13 U/mL were 85.71% and 66.67% respectively. In conclusion, NGAL in urine and bile are remarkably accurate in differentiating pancreatic mass due to chronic pancreatitis from pancreatic adenocarcinoma. Therefore, NGAL concentrations in bile and urine should be further investigated in order to assess their usefulness in early pancreatic adenocarcinoma diagnosis.
- 13 April 2016
- Published by SAGE Publications in Cancer Biomarkers
- Vol. 16 (4) , 537-543
Neutrophil Gelatinase-Associated Lipocalin (NGAL) concentration in urine is superior to CA19-9 and Ca 125 in differentiation of pancreatic mass: Preliminary report
Currently pancreatic cancer is the fourth leading cause of cancer-related death worldwide. Because of its late manifestation and consequent dismal prognosis, there is an urgent need to develop highly sensitive and specific marker. Neutrophil Gelatinase-Associated Lipocalin (NGAL) recently emerged as a protein playing an important role in carcinogenesis of various neoplasms. Our aim was to assess the potential of urine and bile concentration of NGAL in differentiating pancreatic adenocarcinoma from chronic pancreatitis. Forty-two patients operated on due to pancreatobiliary lesions were enrolled in this study. All enrolled patients had eGFR within reference range. Levels of CEA, CA 125 and Ca19-9 were assessed using standard laboratory protocols. A sample of urine was collected prior to the surgery. Intraoperatively a 5 ml sample of bile was collected directly from the common bile duct. Bile and urine levels of NGAL were measured using a ELISA kit. After standard pathological examination of specimens obtained during surgery, patients were divided into 2 groups: 21 patients with pancreatic adenocarcinoma and 15 patients with focal chronic pancreatitis. NGAL concentration in bile in patients with PDAC vs CP was 75.72 ± 16.05 ng/mL vs 62.62 ± 18.6 ng/mL respectively (p= 0,011). NGAL concentration in urine was 43.26 ± 21.21 ng/mL vs 17.96 ± 14.58 ng/mL (p= 0.002) respectively. In order to compare these markers with routinely used ones, ROC curve was built for Ca125 to establish cutoff point and in case of CA19-9 clinically used cutoff (≥ 37U/mL) was applied. Sensitivity and specificity for NGALurine with cutoff value of 27 ng/mL was 80.95% and 80% respectively, while these values for NGALbile were 71.43% and 80% respectively. Ca19-9 measured in plasma with clinically used cutoff value had sensitivity of 71.43% and specificity of 73.33%. Sensitivity and specificity for Ca 125 measured in plasma with cutoff value of 13 U/mL were 85.71% and 66.67% respectively. In conclusion, NGAL in urine and bile are remarkably accurate in differentiating pancreatic mass due to chronic pancreatitis from pancreatic adenocarcinoma. Therefore, NGAL concentrations in bile and urine should be further investigated in order to assess their usefulness in early pancreatic adenocarcinoma diagnosis.
- Open Access
Toxins VapC and PasB from Prokaryotic TA Modules Remain Active in Mammalian Cancer Cells
Among the great number of addictive modules which have been discovered, only a few have been characterized. However, research concerning the adoption of toxins from these systems shows their great potential as a tool for molecular biology and medicine. In our study, we tested two different toxins derived from class II addictive modules, pasAB from plasmid pTF-FC2 (Thiobacillus ferrooxidans) and vapBC 2829Rv (Mycobacterium tuberculosis), in terms of their usefulness as growth inhibitors of human cancer cell lines, namely KYSE 30, MCF-7 and HCT 116. Transfection of the pasB and vapC genes into the cells was conducted with the use of two different expression systems. Cellular effects, such as apoptosis, necrosis and changes in the cell cycle, were tested by applying flow cytometry with immunofluorescence staining. Our findings demonstrated that toxins VapC and PasB demonstrate proapoptotic activity in the human cancer cells, regardless of the expression system used. As for the toxin PasB, observed changes were more subtle than for the VapC. The level of expression for both the genes was monitored by QPCR and did not reveal statistically significant differences within the same cell line.
Open AccessToxins VapC and PasB from Prokaryotic TA Modules Remain Active in Mammalian Cancer Cells
Among the great number of addictive modules which have been discovered, only a few have been characterized. However, research concerning the adoption of toxins from these systems shows their great potential as a tool for molecular biology and medicine. In our study, we tested two different toxins derived from class II addictive modules, pasAB from plasmid pTF-FC2 (Thiobacillus ferrooxidans) and vapBC 2829Rv (Mycobacterium tuberculosis), in terms of their usefulness as growth inhibitors of human cancer cell lines, namely KYSE 30, MCF-7 and HCT 116. Transfection of the pasB and vapC genes into the cells was conducted with the use of two different expression systems. Cellular effects, such as apoptosis, necrosis and changes in the cell cycle, were tested by applying flow cytometry with immunofluorescence staining. Our findings demonstrated that toxins VapC and PasB demonstrate proapoptotic activity in the human cancer cells, regardless of the expression system used. As for the toxin PasB, observed changes were more subtle than for the VapC. The level of expression for both the genes was monitored by QPCR and did not reveal statistically significant differences within the same cell line.